Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.

Literature DB >> 9614013

Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.

A Olujohungbe, K I Cinkotai, A Yardumian.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1998 PMID： 9614013 PMCID： PMC1113271 DOI： 10.1136/bmj.316.7146.1689

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

8 in total

1. Comparison of homozygous sickle cell disease in northern Greece and Jamaica.

Authors: J Christakis; N Vavatsi; H Hassapopoulou; M Papadopoulou; K Mandraveli; D Loukopoulos; J S Morris; B E Serjeant; G R Serjeant
Journal: Lancet Date: 1990-03-17 Impact factor: 79.321

Review 2. Novel treatment options in the severe beta-globin disorders.

Authors: G P Rodgers; E A Rachmilewitz
Journal: Br J Haematol Date: 1995-10 Impact factor: 6.998

3. Pain in sickle cell disease. Rates and risk factors.

Authors: O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney
Journal: N Engl J Med Date: 1991-07-04 Impact factor: 91.245

4. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

Authors: A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban
Journal: Blood Date: 1996-09-15 Impact factor: 22.113

5. Mortality in sickle cell disease. Life expectancy and risk factors for early death.

Authors: O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug
Journal: N Engl J Med Date: 1994-06-09 Impact factor: 91.245

6. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors: S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal: N Engl J Med Date: 1995-05-18 Impact factor: 91.245

7. Sickle cell disease in North London.

Authors: M O Kehinde; J C Marsh; G W Marsh
Journal: Br J Haematol Date: 1987-08 Impact factor: 6.998

8. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.

Authors: P Triadou; M Maier-Redelsperger; R Krishnamoorty; A Deschamps; N Casadevall; O Dunda; R Ducrocq; J Elion; R Girot; D Labie
Journal: Nouv Rev Fr Hematol Date: 1994-10

8 in total

5 in total

Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.

1. Comparison of homozygous sickle cell disease in northern Greece and Jamaica.

Review 2. Novel treatment options in the severe beta-globin disorders.

3. Pain in sickle cell disease. Rates and risk factors.

4. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

5. Mortality in sickle cell disease. Life expectancy and risk factors for early death.

6. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

7. Sickle cell disease in North London.

8. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease.

1. Register cannot replace prospective studies in sickle cell disease.

2. Oxidative stress assessment in sickle cell anemia patients treated with hydroxyurea.

3. European register of patients with sickle cell disease treated with hydroxyurea is being set up.

4. Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study.

5. Experiences of hospital care and treatment-seeking behavior for pain from sickle cell disease: qualitative study.